Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis

Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Kelvin H. M., Lam, Karen S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503858/
https://www.ncbi.nlm.nih.gov/pubmed/28537053
http://dx.doi.org/10.3803/EnM.2017.32.2.145
Descripción
Sumario:Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis. Animal studies have demonstrated a beneficial role of FGF21 in protecting against aberrant lipid profile, while recent development in FGF21 mimetics has provided further insight into the lipid-lowering effects of FGF21 signaling. The present review summarizes the physiological roles of FGF21, and discusses major breakthroughs and limitations of FGF21 mimetic-based therapeutic strategies for treating atherosclerosis.

Ejemplares similares